Hepatic insulin expression improves glycemic control in type 1 diabetic rats

Area of Science:

• Biotechnology
• Endocrinology
• Gene Therapy

Background:

• Type 1 diabetes is characterized by insulin deficiency, leading to hyperglycemia and ketoacidosis.
• Hepatic insulin production has shown potential in preventing diabetic ketoacidosis.
• The role of sustained hepatic insulin production in overall glycemic control requires further investigation.

Purpose of the Study:

• To assess the effects of adenovirus-mediated hepatic insulin production on glycemic control in a type 1 diabetes rat model.
• To determine the dose-dependent relationship between hepatic insulin expression and blood glucose reduction.
• To identify the maximal tolerable level of hepatic insulin production to avoid adverse effects like hypoglycemia.

Main Methods:

• Adenovirus-mediated gene delivery of an engineered rat preproinsulin gene into the livers of streptozotocin-induced diabetic nude rats.
• Monitoring of blood glucose levels, plasma insulin concentrations, and glucose tolerance tests.
• Evaluation of glycemic control during fasting and nonfasting conditions.

Main Results:

• Hepatic insulin production significantly reduced blood glucose levels in treated diabetic rats.
• Moderate insulin levels (0.3-0.7 ng/ml) improved glucose tolerance and maintained euglycemia after a 12-h fast.
• High insulin levels (>1 ng/ml) reversed hyperglycemia but caused severe fasting hypoglycemia.

Conclusions:

• Adenovirus-mediated hepatic insulin production can effectively manage hyperglycemia in type 1 diabetes models.
• A critical balance exists for hepatic insulin production to avoid both hyperglycemia and hypoglycemia.
• This study defines a maximal tolerable level for hepatic insulin production, offering a potential therapeutic strategy for type 1 diabetes.